By PPN News Staff
The FDA approved rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab (Rituxan, Genentech), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia and granulomatosis with polyangiitis and microscopic polyangiitis.
Rituximab-pvvr is a monoclonal antibody (mAb), which works by targeting a protein called CD20, which is present on the surface of B cells. When it attaches to CD20, rituximab helps destroy the B cells.